InsiderClue
Stocks · Health care · Pharmaceutical Preparations

CITIUS ONCOLOGY, INC.

CTOR Clue Score36
United States Fiscal year ends September CIK 0001851484
$0.84 +0.57% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.84 −92.20% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 8 Dec 2022. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2022Operating income−0.1Net income0.4EPS, diluted0.12Fiscal year 2023Net income−12.7 −3,434.3%EPS, diluted−0.19Fiscal year 2023Operating income−1.0Net income2.4EPS, diluted0.27Fiscal year 2024Operating income−20.6Net income−21.1 −974.2%EPS, diluted−0.31Fiscal year 2025Operating income−23.5Net income−24.8EPS, diluted−0.34
FY2022FY2023FY2023FY2024FY2025
Operating income −0.1 n/a −1.0 −20.6 −23.5
Net income 0.4 −12.7 2.4 −21.1 −24.8
Growth −3,434.3% −974.2%
EPS, diluted 0.12 −0.19 0.27 −0.31 −0.34

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2022Operating cash flow−0.0Fiscal year 2023Fiscal year 2023Operating cash flow−0.6Fiscal year 2024Operating cash flow0.1Fiscal year 2025Operating cash flow−5.5
FY2022FY2023FY2023FY2024FY2025
Operating cash flow −0.0 n/a −0.6 0.1 −5.5

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2022Shareholders’ equity0.3Fiscal year 2023Shareholders’ equity25.5Fiscal year 2023Shareholders’ equity−2.0Fiscal year 2024Cash0.0Shareholders’ equity46.1Fiscal year 2025Cash3.9Shareholders’ equity44.9
FY2022FY2023FY2023FY2024FY2025
Cash n/a n/a n/a 0.0 3.9
Shareholders’ equity 0.3 25.5 −2.0 46.1 44.9

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending September, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023 30 Sep 2023 FY2023 31 Dec 2023 FY2024 30 Sep 2024 FY2025 30 Sep 2025
Operations
−0.0 n/a −0.6 0.1 −5.5
Growth −4,446.6%
Investment
−67.3 n/a −1.3 −5.0 −5.8
Financing
67.7 n/a 1.7 4.9 15.2

Capital expenditure, dividends and buybacks are shown as money out, so negative.